Back to top
more

Cencora, Inc. (COR)

(Delayed Data from NYSE)

$278.40 USD

278.40
1,732,273

-5.38 (-1.90%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $278.29 -0.11 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Labcorp (LH) Presents New Research on Precision Diagnostics

by Zacks Equity Research

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Zacks Equity Research

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Zacks Equity Research

Why Is Charles River (CRL) Up 6.2% Since Last Earnings Report?

by Zacks Equity Research

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow

by Zacks Equity Research

GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.

Zacks Equity Research

Charles River (CRL) Extends Gene Therapy Offering With New Pact

by Zacks Equity Research

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Zacks Equity Research

Intuitive Surgical's (ISRG) Da Vinci 5 Receives FDA Approval

by Zacks Equity Research

Intuitive Surgical (ISRG) announces the FDA clearance for its next-generation robotic system, da Vinci 5, which is likely to improve surgical workflow and save significant time with better care.

Zacks Equity Research

BD's (BDX) ADC System Favored by New Study for Long-Term Care

by Zacks Equity Research

BD's (BDX) ADC system is likely to result in improvements in clinical workflow, operational efficiency and financial savings in long-term care facilities.

Zacks Equity Research

Inari Medical's (NARI) ClotTriever Improves Patient Outcome

by Zacks Equity Research

Inari Medical (NARI) announces two-year interim results from the CLOUT registry, which shows a significant improvement in patient's post-thrombotic syndrome and lower rethrombosis-related events.

Zacks Equity Research

Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?

by Zacks Equity Research

Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.

Zacks Equity Research

Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON

by Zacks Equity Research

Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.

Zacks Equity Research

UnitedHealth's (UNH) Payment System Disrupted by Cyberattack

by Zacks Equity Research

A cyberattack on UnitedHealth's (UNH) payment management subsidiary, Change Healthcare, last month continues to impact healthcare services, especially cancer treatments, as payment processing remains disrupted.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.

Zacks Equity Research

AMN Healthcare (AMN) Expands Capabilities of ShiftWise Flex

by Zacks Equity Research

AMN Healthcare's (AMN) expansion of the capabilities of ShiftWise Flex is likely to enhance internal resource pool management for the healthcare system.

Zacks Equity Research

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy as Industry Trends Improve

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most. However, staffing shortages continue to disrupt the growth trend.

Zacks Equity Research

Philips (PHG), AWS Unite to Scale Digital Pathology Solutions

by Zacks Equity Research

Philips (PHG) collaborates with Amazon Web Services to boost cloud-based pathology solutions. It will enable pathology laboratories to use digital processes to improve analytical capabilities.

Zacks Equity Research

PacBio's (PACB) New Panel to Aid Its Clinical Research Solution

by Zacks Equity Research

PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.

Zacks Equity Research

Why Cencora (COR) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Integra LifeSciences (IART) Introduces MicroMatrix Flex

by Zacks Equity Research

Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.

Zacks Equity Research

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Zacks Equity Research

ClearPoint's (CLPT) Prism System Favored by Latest Study

by Zacks Equity Research

ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.

Zacks Equity Research

Here's Why You Should Retain BD (BDX) to Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches raises optimism about the stock.

Zacks Equity Research

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Zacks Equity Research

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion

by Zacks Equity Research

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.